Jobs in Australia. 34 jobs to view and apply for now with PharmiWeb.jobs
Atomic AI, a biotechnology company fusing cutting-edge machine learning with state-of-the-art structural biology to unlock RNA drug discovery, announced that the Company has created the first large language model (LLM) leveraging chemical mapping data. In a preprint paper published on bioRxiv, Atomic AI describes its proprietary ATOM-1™ platform component, a foundation model that can accurately predict the structure and function of RNA and help dramatically improve development of RNA therapeutics.
AdvanCell, a radiopharmaceutical company developing a pipeline of Targeted Alpha Therapies for cancer patients, today announced the first patient was treated with 212Pb-ADVC001, a Targeted Alpha Therapy in development for the treatment of PSMA-positive metastatic CastrationResistant Prostate Cancer (mCRPC).
Oxolife, the specialist biotech focused on enhancing embryo implantation in women undergoing Assisted Reproductive Technology (ART) fertility treatment, today announces it has appointed globally renowned fertility experts to its Scientific Advisory Board (SAB).
Innovaderm Research Inc. is a specialized CRO with a dual focus on dermatology and rheumatology. We assist biopharmaceutical sponsors in initiating and completing clinical trials.
Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions.
Chemify, a deep tech chemical science company combining chemistry, robotics and AI at scale to digitally design, discover and make new molecules, announced today that Michael Bell has joined as Chief Technology Officer.
Ottimo Pharma (“Ottimo”), an innovative biotech company developing one-of-a-kind PD1/VEGFR2 dual pathway antibodies to extend the lives of patients living with cancer, today announces the appointment of Robert Tighe as Senior Vice President of Preclinical and Translational Sciences.
AlgoTherapeutix (AlgoTx) is a clinical stage biotechnology company developing a targeted, first in class therapeutic for peripheral neuropathic pain.
On November 6th 2023, Vaccitech announced that the company had changed its name to Barinthus Biotherapeutics plc to represent the evolution and expansion of its focus beyond vaccines. Here, we introduce Barinthus Bio with insights from the company into the meaning behind the rebrand and goals for future growth.
LoQus23 Therapeutics Ltd (“LoQus23”), a private biotechnology company investigating small molecule drugs that could stop the pathogenic triplet expansion that is the cause and driver of Huntington’s Disease, myotonic dystrophy type 1, and other triplet repeat expansion diseases, today announces the appointment of Dr Cyrus Mozayeni as its Chair of the Board of Directors.
OPEN Health unites deep scientific knowledge with wide-ranging specialist expertise to unlock possibilities that improve health outcomes and patient well-being. Working in partnership with our clients, we embrace our different perspectives and strengths to deliver fresh thinking and solutions that make a difference.
Aplagon is a clinical stage biopharmaceutical company developing a first-in-class therapeutic APAC for treating thrombo-inflammatory diseases.
The UK biotech sector secured a substantial total of £563 million in venture capital and public financing during the three months spanning June to August 2023, data published today by the UK BioIndustry Association (BIA) and Clarivate shows.
ENA Respiratory is a clinical-stage pharmaceutical company tackling serious respiratory viral infections through the development of host defense immune enhancers which locally prime and boost the body’s innate immune response – the natural first line of defence against invading pathogens.
The Institute of Cancer Research, London, has been granted the highest national honour in UK further and higher education for its innovative work on breast cancer.
Vortex Biotech Holdings, (‘Vortex’, or ‘the Company’), a leading oncology liquid biopsy company, is pleased to announce the appointment of Nigel Brooksby as Non-Executive Chairman.
Engimmune Therapeutics is a world-class developer of highly targeted, highly potent ‘off-the-shelf’ soluble T-cell receptor drugs (TCRs) to treat solid tumours.
The Oxford-Harrington Rare Disease Centre (‘OHC’), a partnership between the University of Oxford, UK and Harrington Discovery Institute at University Hospitals, Cleveland, Ohio, aimed at driving cutting-edge rare disease breakthroughs, announces the appointment of Matthew Anderson, MD, PhD, as co-Director.
Molex, a global electronics leader and connectivity innovator, today announced a major expansion of its global manufacturing footprint with the opening of a new campus in Katowice, Poland.
